146 related articles for article (PubMed ID: 22942815)
1. Less than ideal: how oncologists practice with limited drug access.
Chan KK; Wong B; Siu LL; Straus SE; Chang J; Berry SR
J Oncol Pract; 2012 May; 8(3):190-5. PubMed ID: 22942815
[TBL] [Abstract][Full Text] [Related]
2. Variation and consternation: access to unfunded cancer drugs in Canada.
Berry SR; Evans WK; Strevel EL; Bell CM
J Oncol Pract; 2012 Jan; 8(1):35-9. PubMed ID: 22548009
[TBL] [Abstract][Full Text] [Related]
3. Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists.
Wong SK; Gondara L; Gill S
Curr Oncol; 2021 Nov; 28(6):4748-4755. PubMed ID: 34898584
[TBL] [Abstract][Full Text] [Related]
4. Overcoming obstacles in accessing unfunded oral chemotherapy: physician experience and challenges.
Han D; Trinkaus M; Hogeveen S; Mamdani M; Berry SR; Jang RW; Hoch JS; Simmons C
J Oncol Pract; 2013 Jul; 9(4):188-93. PubMed ID: 23942919
[TBL] [Abstract][Full Text] [Related]
5. Recommending Unfunded Innovative Cancer Therapies: Ethical vs. Clinical Perspectives among Oncologists on a Public Healthcare System-A Mixed-Methods Study.
Bashkin O; Dopelt K; Asna N; Davidovitch N
Curr Oncol; 2021 Aug; 28(4):2902-2913. PubMed ID: 34436020
[TBL] [Abstract][Full Text] [Related]
6. Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
van Nassau SC; Bond MJ; Scheerman I; van Breeschoten J; Kessels R; Valkenburg-van Iersel LB; Verheul HM; Buffart TE; Mekenkamp LJ; Lemmens VE; Koopman M; Bol GM;
JAMA Netw Open; 2021 Sep; 4(9):e2124766. PubMed ID: 34505885
[TBL] [Abstract][Full Text] [Related]
7. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
[TBL] [Abstract][Full Text] [Related]
8. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Provincial Lung Disease Site Group of Cancer Care Ontario.
Graham ID; Evans WK; Logan D; O'Connor A; Palda V; McAuley L; Brouwers M; Harrison MB
Oncology; 2000 Nov; 59(4):283-90. PubMed ID: 11096339
[TBL] [Abstract][Full Text] [Related]
9. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
[TBL] [Abstract][Full Text] [Related]
10. Breast Medical Oncologists' Perspectives of Telemedicine for Breast Cancer Care: A Survey Study.
Stavrou E; Qiu J; Zafar A; Tramontano AC; Isakoff S; Winer E; Schrag D; Manz C
JCO Oncol Pract; 2022 Sep; 18(9):e1447-e1453. PubMed ID: 35671420
[TBL] [Abstract][Full Text] [Related]
11. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
[TBL] [Abstract][Full Text] [Related]
12. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
Berry SR; Hubay S; Soibelman H; Martin DK
BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
[TBL] [Abstract][Full Text] [Related]
13. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.
Fundytus A; Sengar M; Lombe D; Hopman W; Jalink M; Gyawali B; Trapani D; Roitberg F; De Vries EGE; Moja L; Ilbawi A; Sullivan R; Booth CM
Lancet Oncol; 2021 Oct; 22(10):1367-1377. PubMed ID: 34560006
[TBL] [Abstract][Full Text] [Related]
14. A preliminary survey of oncologists' perceptions of quality of life information.
Bezjak A; Ng P; Taylor K; MacDonald K; Depetrillo AD
Psychooncology; 1997 Jun; 6(2):107-13. PubMed ID: 9205968
[TBL] [Abstract][Full Text] [Related]
15. Discussing and prescribing expensive unfunded anticancer drugs in Australia.
Karikios DJ; Mileshkin L; Martin A; Ferraro D; Stockler MR
ESMO Open; 2017; 2(2):e000170. PubMed ID: 28761744
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
17. Perceptions and attitudes of medical oncologists regarding fertility preservation and pregnancy in high-risk cancer patients: A survey among Canadian medical oncologists.
Alshamsan B; Kushnir I; Al-Saadi S; Srikanthan A
Cancer Med; 2023 Jan; 12(2):1912-1921. PubMed ID: 35833372
[TBL] [Abstract][Full Text] [Related]
18. Virtual Management of Patients With Cancer During the COVID-19 Pandemic: Web-Based Questionnaire Study.
Tashkandi E; Zeeneldin A; AlAbdulwahab A; Elemam O; Elsamany S; Jastaniah W; Abdullah S; Alfayez M; Jazieh AR; Al-Shamsi HO
J Med Internet Res; 2020 Jun; 22(6):e19691. PubMed ID: 32501807
[TBL] [Abstract][Full Text] [Related]
19. Medical Oncologists' Knowledge and Perspectives on the Use of Biosimilars in the United States.
Peipert JD; Kaiser K; Kircher S; Greene GJ; Shaunfield S; Hauner K; Cella D; Mroczek DK
JCO Oncol Pract; 2023 Mar; 19(3):e457-e464. PubMed ID: 36623249
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
